The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Redefining MGUS to better predict progression to active disease
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares her thoughts on the diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), and how the field needs to move forward, with regard to understanding, identifying, and treating precursor conditions. Dr Ghobrial notes the importance of establishing when MGUS develops from a normal phenotype into a malignant phenotype and which patients are most at risk of progression to overt disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
